Prof. Dr. Stefan Dübel

Prof. Dr. Stefan Dübel

Prof. Dr. Stefan Dübel

Room: P101c
Phone: +49.531.391.5731
Fax: +49.531.391.5763
e-mail: biotech(at)

Stefan Dübel is full Professor of Biotechnology and Director of the respective department at the Technische Universität Braunschweig, Germany. He further serves as director of the technology transfer unit "Centre for Molecular Engineering" of iTUBSmbH and as consultant to biotech / pharma companies and US/EU government institutions. He initiated the "Antibody factory" of the German National Genome Research Network and is editor of the four volume reference "Handbook of Therapeutic Antibodies" and several other antibody engineering books. He is co-founder of five biotech spin-offs and initiated CORAT Therapeutics which developed a human anti-SARS-CoV-2 antibody against COVID-19 to clinical trials within less than a year. 

After obtaining his Ph.D. from the University of Heidelberg, in 1989 he joined the German Cancer Research Center (DKFZ) where he co-pioneered in vitro antibody selection technologies, resulting in several key inventions including antibody phage display (e.g. US Patent 5849500), human antibody libraries (e.g. US6319690) and antibody libraries with randomized CDRs (e.g. US Patent 5840479). His lab continued to contribute to multiple topics related to human antibody engineering, phage display and in vitro evolution, e.g. the now industry standard "Hyperphage" technology (2001), ORFeome display (2006), targeted RNases for cancer therapy (1995/2008) and a universal allosteric switch module for antibody affinity (2017). He continued to promote and adapt phage display for the generation of research antibodies in several international consortia (Affinity Proteome, Affinomics, SGC), culminating in the demonstration that the ubiquitous polyclonal secondary antibodies can be replaced by animal-free multiclonal antibodies (2020). His work resulted in >250 publications and >25 patent applications.

Research topics

Antibody Engineering, Phage Display, anti-cancer-Antibodies, Intrabodies, in vitro Evolution, Synthetic Biology, Biosensors, Sneaking Ligands, Hyperphage, SARS-CoV-2 neutraliszing antibodies

Curriculum vitae
1978-1982 Studies of Biology at the Universities of Mainz and Heidelberg, Germany 

1982-1983 Diploma thesis in Botany at the Max-Planck Institute for Cell Biology in Ladenburg, Germany on "Developmental Biology of the Green Algae Acetabularia"

1984-1985 Zivildienst: Research on "Diagnostic Tools for Autoimmune Diseases" at the Institute of Immunology, University of Heidelberg.

1986-1989 PhD thesis at the Centre for Molecular Biologiy Heidelberg (ZMBH) on "Cell Cycle Regulation and Cell Differentiation in the Coelenterate Hydra", Promotion (Dr. rer. nat.) summa cum laude.

8/1989-7/1991 Post-Doc at the German Cancer Research Centre, Heidelberg (DKFZ) with a project on "Generation and Screening of E. coli Libraries of Recombinant Antibodies" 

1/1992-7/1992 Work on "Recombinant Antibodies Against TNF Receptor" at the Institute of Cell Biology and Immunology, University of Stuttgart, Germany

8/1992-9/1996 Work on "Recombinant Antibodies, Immunotoxins and Phage Display Screening Technologies" at the German Cancer Research Centre, Heidelberg (DKFZ)

1996-2001 Group leader of the "Recombinant Antibody Unit" at the Department of Molecular Genetics, University of Heidelberg

6/1997 Habilitation (Faculty of Biology), University of Heidelberg

2/2001 Appointed "Hochschuldozent" at the University of Heidelberg

2001-2002 CSO and Member of the Directory Board of LifeBits AG

Oct 2002 - today Full Professor and Director of the Department of Biotechnology, Technical University of Braunschweig, Germany

1989 "Stipendium zur Förderung des herausragenden wissenschaftlichen Nachwuchses" des Deutschen Krebsforschungszentrums Heidelberg


More Information